[Power Alley Part II:] HSBC ALSO Boosts Gilead's 12 Month Price Target Significantly. The House Calls It A "Buy". That Is Correct.

See the immediately prior one, for why you would be wise to trust this very long-standing institution's financial calls. And know that, having personally dealt with the bank -- on mulitple multi-billion dollar deals (representing multi-national life science and pharma concerns), it runs a very tight ship. In this 2020s world of crypo-bros, and morons buying SMELANIA meme-coins. . . that is a very distinguished mark, and brand.

So. . . without any additional ado [but do recall that we mentioned in January a $156 target, from Citi] -- here is that '34 Act registered securities pricing/trading update:

. . .HSBC upgraded Gilead Sciences to Buy from Hold on Monday and raised its price target to $155 from $133.

The firm said the market is too pessimistic on the HIV market following the introduction of dolutegravir generics. HSBC believes long-acting HIV therapies will improve adherence and help offset declines, supporting better-than-consensus HIV forecasts.

The analyst cited potential short-term upside from high-growth PrEP product Yeztugo and oncology catalysts including anito-cel and Trodelvy.

HSBC noted the recent share price correction has made the valuation attractive. . . .

This is where the market is headed: safe, high cash flow names -- in bio-science and pharma. Trust that, with chaos the only brand in DC, these next two and a half years.

नमस्ते